Research programme: cannabinoid CB2 receptor agonists - AbbVie

Drug Profile

Research programme: cannabinoid CB2 receptor agonists - AbbVie

Alternative Names: A-796260

Latest Information Update: 22 Jan 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Indoles; Morpholines; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 29 Mar 2012 Pharmacodynamics data from a preclinical trial in pain presented at the 243rd American Chemical Society National Meeting (243rd-ACS-2012)
  • 08 Sep 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top